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Abstract Duringassembly,HLAclassIImoleculesassociate
with the invariant chain. As the result, the peptide-binding
groove isoccupied by an invariant chain peptide termedCLIP
(class-II-associated invariant chain peptide; sequence
MRMATPLLM). By mass spectrometry, we have now
characterized peptides that are naturally present in HLA-
DQ2. This analysis revealed that 22 variants of Ii-derived
peptides are associated with HLA-DQ2. Strikingly, the large
majority of those do not contain the conventional CLIP
sequence MRMATPLLM, but instead a peptide that partially
overlaps with CLIP, sequence TPLLMQALPM. Peptide
binding studies indicate that this alternative CLIP peptide
has superior HLA-DQ2 binding properties compared to the
conventional CLIP and that the minimal nine-amino-acid
binding core consists of the sequence PLLMQALPM,
findings that could be corroborated by molecular simulation.
The alternative CLIP peptide was also found to be present in
HLA-DQ2 molecules isolated from human thymus. More-
over, the alternative CLIP peptide was also found in
association with HLA-DQ8. Together, these results indicate
that HLA-DQ2 and HLA-DQ8 associate with an alternative
CLIP sequence, a property that may relate to the strong
association between HLA-DQ molecules and human auto-
immune diseases.
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Introduction
The MHC class II α and β subunits associate with an
invariant chain (Ii) trimer shortly after biosynthesis in the
endoplasmic reticulum, generating a stable complex (Roche
et al. 1991). Part of the Ii-chain, commonly referred to as
CLIP (class-II-associated invariant chain peptide), occupies
the peptide-binding groove of MHC class II molecules, thus
preventing peptide loading in the endoplasmatic reticulum
(Bakke and Dobberstein 1990). Moreover, Ii facilitates the
transport of the MHC class II molecules to the endosomal
compartment where Ii is degraded by proteases. Subse-
quently, CLIP is released from the groove by the catalytic
action of HLA-DM and exchanged for immunogenic
peptides derived from proteins that have entered the
endosomal/phagolysosomal system (Rocha and Neefjes
2008). Several autoimmune diseases, including type I
diabetes and celiac disease, are HLA-associated.
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La Jolla, CA 92037, USAIn a recent study, we have reported the characterization
of a large number of naturally HLA-DQ2-bound peptides
through mass spectrometry (Stepniak et al. 2008). In
agreement with two previous studies, the most abundant
peptide identified was the HLA-class-I-derived peptide
IEQEGPEYW (van de Wal et al. 1996, Vartdal et al.
1996). Similarly, the second most abundant peptide was
found to be invariant chain (li)-derived (van de Wal et al.
1996;Vartdal et al. 1996). We estimate that at least 10% of
all HLA-DQ2 molecules is occupied by an invariant-chain-
derived peptide. Twenty-two invariant-chain-derived pep-
tides were identified, and a minimal core of ten amino acids
was found to be present in all length variants [sequence
TPLLMQALPM (CLIP 94–103); Fig. 1a]. Surprisingly, the
sequence TPLLMQALPM was distinct from the CLIP
peptide MRMATPLLM (CLIP 90–98) found to occupy the
binding groove of all other human and murine class II
molecules investigated (Chapman 1998). To determine the
ratio between the CLIP and the alternative CLIP peptide in
HLA-DQ2, we determined the relative abundance of the
length variants of the Ii-derived peptides by mass spec-
trometry. This was done by integration of selected peaks in
the mass chromatograms, done under the assumption that
the relative response is similar for these species, which is
appropriate since these species are length variants. The vast
majority (approximately 90%) of the Ii-derived peptides
contained the alternative CLIP sequence, while 10%
contained the CLIP sequence (Fig. 1a).
To test if the alternative CLIP peptide is also present in
HLA-DQ2 molecules expressed in the human thymus, we
affinity purified HLA-DQ2 molecules from the thymus of
two approximately 1.5-year-old HLA-DQ2-positive chil-
dren. Subsequently, the bound peptides were eluted and
characterized by mass spectrometry. A single Ii-derived
peptide was identified which contained the CLIP sequence:
TPLLMQALMGALPQ (CLIP 94–107; Fig. 1b). This
peptide is identical to one of the most abundant peptides
found in HLA-DQ2 molecules purified from an Epstein–
Barr virus (EBV)-transformed cell line (Fig. 1a). Together,
this indicates that also in the thymus, the alternative CLIP
peptide is present in HLA-DQ2.
Two peptides, containing either CLIP (MRMATPLLM
QAL; CLIP 90–101) or the alternative sequence (ATPL
LMQALPMGALP; CLIP 93–107), were tested for their
capacity to bind to HLA-DQ2 in a cell-free competition
assay (Fig. 2a). The results showed a significantly lower
IC50 value for the alternative CLIP sequence ATPLLM
QALMGALP (CLIP 93–107), indicating a higher binding
affinity. We further tested two nonamers containing CLIP
(MRMATPLLM; CLIP 90–98) and the predicted binding
frame of the alternative CLIP (PLLMQALPM: termed
DQ2-CLIP hereafter; Fig. 2a) again showing a fourfold
lower IC50 for DQ2-CLIP.
To test the predicted binding frame of the DQ2-CLIP
sequence, we next analyzed the binding of N- and C-
terminally truncated length variants of CLIP 92–107
(MATPLLMQALPMGALP; Fig. 2b). Deletion of P95 and
M103 was found to abrogate binding almost completely,
indicating PLLMQALPM (CLIP 95–103) as the nine-
amino-acid binding core.
To study the binding of DQ2-CLIP in more detail, we
next determined which amino acids function as anchor
residues in PLLMQALPM (CLIP 95–103). For this
purpose, the impact of systematic substitution of amino
acids in PLLMQALPM by lysine (K) was determined
(Fig. 2c). Most dramatic effects could be seen for
substitutions at positions p1, p4, p6, and p9, known to be
important anchor positions where no positive charges are
allowed. In addition, strong effects could also be seen at the
p7 anchor position and the non-anchor position p8. This
latter observation may reflect the preference of HLA-DQ2
for a proline at the p8 position (Stepniak et al. 2008).
Additionally, modeling of HLA-DQ2 complexed with the
peptidePLLMQALPMshowedthatitfitswellinthegrooveof
HLA-DQ2 (Fig. 3a and b). Moreover, it is predicted to bind
better than the conventional CLIP peptide MRMATPLLM
(unpublished data), a prediction that is confirmed by the
observed superior binding of DQ2-CLIP (Fig. 2a).
Since the spacing of the anchor residues in DQ2-CLIP is
identical to that of the dominant HLA-class-I-derived
peptide IEQEGPEYW (van de Wal et al. 1996; italicized
amino acids are residues at anchor positions) as well as
gluten-derived T cell stimulatory peptides (Vader et al.
2003), we conclude that the DQ2-CLIP peptide binds to
HLA-DQ2 molecules in a similar binding register. In
conclusion, the minimal core sequence within the DQ2-
CLIP peptide that binds strongly to HLA-DQ2 is
PLLMQALPM (residues 95–103) in which the italicized
amino acids are residues at anchor positions.
Because celiac disease and type I diabetes are also
associated with HLA-DQ8, we also analyzed naturally
HLA-DQ8-bound peptides through mass spectrometry. The
invariant chain was represented again by 22 peptides with a
minimal core of ten amino acids present in all length
variants, which is identical to that found in HLA-DQ2
[sequence TPLLMQALPM (CLIP 94–103); data not
shown]. In adidtion, binding studies revealed that the
peptide ATPLLMQALPMGALP (CLIP 93–107) binds
slightly better than the peptide MRMATPLLMQAL (CLIP
90–101; data not shown). These results thus indicate that
next to HLA-DQ2, HLA-DQ8 also appears to harbor an
alternative CLIP peptide. Further studies will be required to
determine the exact binding frame of this alternative CLIP
peptide in HLA-DQ8.
It is now widely accepted that positive selection in the
thymus is promiscuous (Ignatowicz et al. 1996), that is, a
552 Immunogenetics (2008) 60:551–555single self-peptide is able to mediate positive selection of
large numbers of T cells with the ability to respond to
various peptide antigens (Ignatowicz et al. 1997). It has also
been demonstrated that in mice lacking DM molecules
required for the dislocation of CLIP from MHC class II
(Fukui et al. 1997; Martin et al. 1996), 15–50% of the
normal number of CD4
+ T cells are selected. Moreover, the
T cell receptor repertoire in these mice was different from
that in wild-type mice, suggesting that MHC class II–CLIP
complexes can select a large and diverse repertoire of T
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Fig. 1 Identification of an
alternative CLIP peptide in
HLA-DQ2. A Alignment of the
length variants of the invariant-
chain-derived peptides present
in HLA-DQ2 expressed on
EBV-transformed B cells. The
solid line marks the predicted
alternative CLIP sequence
specific for HLA-DQ2; the
dashed line marks the CLIP
sequence found in other HLA
class II molecules. B Tandem
mass spectrum of one of
DQ2-CLIP peptides. The amino
acid sequence of the peptide is
indicated on top of the spectrum,
including the expected b- and
y-fragment ions. Observed
fragment ions are underlined
and indicated in the spectrum.
The correct identity of the
peptide was proven by tandem
mass spectrometry of the
synthetic compound
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DQ2, it is therefore possible that a substantial proportion of
HLA-DQ2-restricted T cells in the periphery has been
selected by HLA-DQ2–[DQ2-CLIP] complexes in the
thymus. As HLA-DQ8 also appears to harbor an alternative
CLIP peptide, this may similarly apply to T cell receptor
selection in HLA-DQ8 individuals. It is tempting to
speculate that this relates to the fact that HLA-DQ2 and
HLA-DQ8 confer susceptibility for the common autoim-
mune diseases celiac disease and type I diabetes (Nepom
and Kwok 1998; Todd et al. 1987).
Concluding remarks
In conclusion, we have observed that HLA-DQ2 molecules
preferentially associate with an alternative form of the
invariant-chain-derived CLIP peptide, DQ2-CLIP. The
DQ2-CLIP has an at least four times higher binding affinity
to HLA-DQ2 than the previously described classical CLIP
sequence. Similarly, we observed that HLA-DQ8 harbors
an alternative CLIP peptide. This property may relate to the
strong association between these HLA-DQ molecules and
human autoimmune diseases.
a
b
Fig. 3 Computer modeling of DQ2-CLIP in association with HLA-
DQ2 based on the known DQ2-structure. A Side view of the DQ2-
CLIP peptide (Ii 94–104) as it appears in complex with HLA-DQ2. B
Shown is the TCR view of HLA-DQ2 (A1*0501/B1*0201) in
complex with the DQ2-CLIP peptide (94–104 of Ii; core nonamer
96–104). The HLA-DQ2 molecule is shown in a van der Waals
surface representation color coded according to the atomic charges
(positive, blue; negative, red; neutral, gray); the surfaces for four
residues (α76Arg, β61Trp, β70Arg, β71Lys) are transparent so that
the respective residues can all be made visible. The peptide is shown
in space filling mode (atomic color code: carbon, green; oxygen, red;
nitrogen, blue; hydrogen, white; sulfur, yellow)
Fig. 2 Identification of an alternative CLIP sequence. A Binding of
two versions of the CLIP peptide to HLA-DQ2 and the binding of the
predicted minimal core of DQ2-CLIP (PLLMQALPM). B Binding of
a series of truncated versions of CLIP 90–105 to HLA-DQ2. C
Binding of a series of CLIP 93–101 lysine substitution analogues.
Gray columns indicate an IC50 above 200 μM representing weak or no
binding. Each peptide was tested in at least two independent
experiments; representative results are shown
554 Immunogenetics (2008) 60:551–555Acknowledgments This research has been supported by a Marie
Curie Fellowship of the European Community programme Drugs for
Therapy under the contract number MRTN-CT-2004-512385 and the
Celiac Disease Consortium, an Innovative Cluster approved by the
Netherlands Genomics Initiative, and partially funded by the Dutch
Government (BSIK03009). The authors thank B.O. Roep and J. van
Bergen for critically reading the manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Bakke O, Dobberstein B (1990) MHC class II-associated invariant
chain contains a sorting signal for endosomal compartments. Cell
63:707–716
Chapman HA (1998) Endosomal proteolysis and MHC class II
function. Curr Opin Immunol 10:93–102
Fukui Y, Ishimoto T, Utsuyama M, Gyotoku T, Koga T, Nakao K,
Hirokawa K, Katsuki M, Sasazuki T (1997) Positive and negative
CD4
+ thymocyte selection by a single MHC class II/peptide ligand
affected by its expression level in the thymus. Immunity 6:401–410
Ignatowicz L, Kappler J, Marrack P (1996) The repertoire of T cells
shaped by a single MHC/peptide ligand. Cell 84:521–529
Ignatowicz L, Rees W, Pacholczyk R, Ignatowicz H, Kushnir E,
Kappler J, Marrack P (1997) T cells can be activated by peptides
that are unrelated in sequence to their selecting peptide.
Immunity 7:179–186
Martin WD,Hicks GG, MendirattaSK, LevaHI, RuleyHE, Van Kaer L
(1996) H2-M mutant mice are defective in the peptide loading of
class II molecules, antigen presentation, and T cell repertoire
selection. Cell 84:543–550
Nepom GT, Kwok WW (1998) Molecular basis for HLA-DQ
associations with IDDM. Diabetes 47:1177–1184
Rocha N, Neefjes J (2008) MHC class II molecules on the move for
successful antigen presentation. EMBO J 27:1–5
Roche PA, Marks MS, Cresswell P (1991) Formation of a nine-
subunit complex by HLA class II glycoproteins and the invariant
chain. Nature 354:392–394
Stepniak D, Wiesner M, de Ru AH, Moustakas AK, Drijfhout JW,
Papadopoulos GK, van Veelen PA, Koning F (2008) Large-scale
characterization of natural ligands explains the unique gluten-
binding properties of HLA-DQ2. J Immunol 180:3268–3278
Todd JA, Bell JI, McDevitt HO (1987) HLA-DQ beta gene contributes
to susceptibility and resistance to insulin-dependent diabetes
mellitus. Nature 329:599–604
Vader W, Stepniak D, Kooy Y, Mearin ML, Thompson A, Spaenij L,
Koning F (2003) The HLA-DQ2 gene dose effect in Celiac
Disease is directly related to the magnitude and breadth of
gluten-specific T-cell respnoses. Proc Natl Acad Sci USA
100:12390–12395
van de Wal Y, Kooy YMC, Drijfhout JW, Amons R, Koning F (1996)
Peptide binding characteristics of the coeliac disease-associated
DQ(alpha1*0501, beta1*0201) molecule. Immunogenetics
44:246–253
Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanovic S, Eriksen JE,
Sletten K, Thorsby E, Rammensee HG, Sollid LM (1996)
The peptide binding motif of the disease associated HLA-DQ
(alpha 1* 0501, beta 1* 0201) molecule. Eur J Immunol 26:2764–
2772
Immunogenetics (2008) 60:551–555 555